EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Pilot prospective crossover study assessing the role of bile acid malabsorption in the causation and treatment of major low anterior resection syndrome: randomized clinical trial

John C Woodfield, Kari A Clifford iD, Rohan Thomas, Simon J G Richards, Anna Kate Fowler, Mohammad K Alquassab, Chrissie Roodt, Mark W Thompson-Fawcett iD

BJS Open · 03.11.2026 · 10 (6)

DOI: 10.1093/bjsopen/zrag141 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJS Open, online erschienen am 13.11.2026. Verfasst von John C Woodfield und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Critical Care, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Bile Acids and Salts, Colesevelam Hydrochloride, Low Anterior Resection Syndrome, Malabsorption Syndromes. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Zealand Lottery Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major low anterior resection syndrome (LARS) affects approximately 60% of rectal cancer survivors, causing urgency and decreased bowel control, reducing quality of life. Bile acid malabsorption (BAM) is an under-recognized contributor whose prevalence and treatment efficacy remain unclear. This proof-of-concept study evaluated the effectiveness of colesevelam for treating LARS and described the prevalence of BAM.

Methods

This double-blind randomized placebo-controlled crossover trial was conducted between 2021 and 2024 in New Zealand. Adults aged 18–85 years with major LARS received colesevelam (up to 1.25 g, three times daily) or placebo for 5 weeks, separated by a 6-week washout period. A subset of patients underwent 75-selenium homocholic acid taurine (SeHCAT) testing for BAM. The outcomes of interest included changes in the LARS score, Fecal Incontinence Quality of Life Scale (FIQL), and Short-Form 12 (SF-12) questionnaire, with a composite outcome reflecting clinically important improvements.

Results

Of 80 eligible patients, 49 were randomized. However, 36 patients completed the study after washout and were included in a per-protocol analysis (mean age 71 years; 69% male). In these 36 patients, colesevelam did not significantly improve LARS scores, but did significantly improve the SF-12 mental component summary (median +2.36; 95% confidence interval 0.00 to 10.25; P < 0.01) and FIQL depression/self-perception. Eight of 19 patients (42%) had BAM and exhibited significant improvements in SF-12 physical and mental item scores with colesevelam. Using composite criteria, colesevelam produced a 33% response rate, versus 8% for placebo, with higher rates in BAM-positive (50%) than BAM-negative (11%) patients.

Conclusions

BAM is a treatable contributor to LARS, present in 40% of tested patients. Although treating all LARS patients with bile acid sequestrants provides limited benefit, SeHCAT testing identifies patients likely to respond. BAM assessment would be beneficial if incorporated into LARS management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Acids and SaltsColesevelam HydrochlorideLow Anterior Resection SyndromeMalabsorption SyndromesAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesDouble-Blind MethodPilot ProjectsProspective StudiesQuality of LifeRectal NeoplasmsTreatment Outcome

Stichwörter der Autor:innen

LARScolesevelamcolorectal surgeryquality of life

Substanzen

Bile Acids and SaltsColesevelam Hydrochloride

Autor:innen und Institutionen

  • Department of Surgery and Critical Care, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
  • Department of Surgery, Kew Hospital, Invercargill, New Zealand.
  • Department of Surgery and Critical Care, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand.
  • Department of Surgery, Dunedin Hospital, Dunedin, New Zealand.

ORCID-Profile: Kari A Clifford, Mark W Thompson-Fawcett

Förderung

  • New Zealand Lottery Health

Zitieren

APA

Woodfield, J. C., Clifford, K. A., Thomas, R., Richards, S. J. G., Fowler, A. K., Alquassab, M. K., Roodt, C., & Thompson-Fawcett, M. W. (2026). Pilot prospective crossover study assessing the role of bile acid malabsorption in the causation and treatment of major low anterior resection syndrome: randomized clinical trial. BJS Open, 10(6). https://doi.org/10.1093/bjsopen/zrag141

Vancouver

Woodfield JC, Clifford KA, Thomas R, Richards SJG, Fowler AK, Alquassab MK, et al. Pilot prospective crossover study assessing the role of bile acid malabsorption in the causation and treatment of major low anterior resection syndrome: randomized clinical trial. BJS Open. 2026;10(6). doi:10.1093/bjsopen/zrag141

BibTeX
@article{Woodfield2026,
  author = {Woodfield, John C and Clifford, Kari A and Thomas, Rohan and Richards, Simon J G and Fowler, Anna Kate and Alquassab, Mohammad K and Roodt, Chrissie and Thompson-Fawcett, Mark W},
  title = {Pilot prospective crossover study assessing the role of bile acid malabsorption in the causation and treatment of major low anterior resection syndrome: randomized clinical trial},
  journal = {BJS Open},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1093/bjsopen/zrag141}
}
Kostenlos starten →